TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Improving Access to Psychiatric Care for Patients in Primary Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 15 years patient or older:~* presenting mental suffering or a frequent or severe mental disorder~* having consulted his GP who ask for psychiatric consultation~* having given its consent for the use of its medico-administrative data~* affiliated with the general health insurance scheme~* of which the GP is from Haute Garonne and is voluntary to participate in the study~* Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research) and by one of the parents for minor participants~Exclusion Criteria:~* Patient with ongoing psychiatric follow-up~* Patient unable to answer questionnaires (unable to read or write)~* Patients receiving a measure of legal protection

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Shared care device in psychiatry (DSPP) (Type: EXPERIMENTAL): System focused on collaboration between general medicine (GP) and psychiatry, offering psychiatric assessment consultations and guidance for patient addressed by his/her GP. Referrals are made to the GP with support for care or the patient can be oriented to routine psychiatric care.
- Care as usual (Type: ACTIVE_COMPARATOR): Patient will have usual care :~Psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Exploration of Pupil Dilation in Horner's Patients Taking Flomax

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Horner's Syndrome~2. History of taking an alpha blocker (tamsulosin/ terazosin/doxazosin/alfuzosin/silodosin) medication~Exclusion Criteria:~1. Subjects with untreated hypertension~2. Subjects with thyrotoxicosis~3. Pregnant women~4. Prisoners~5. Inability to consent~6. Subjects with anatomical narrow angles who have never had a dilated exam

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 10% phenylephrine (Type: OTHER): All patients will receive 10% phenylephrine at their eye examination as the drug to dilate the pupil. After pupil dilation, pupil size will be measured.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of ADG20 for the Prevention of COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Tests negative for current or previous SARS-CoV-2 infection by RT-PCR and serology (Pre-exposure population only)~* Is at high risk of SARS-CoV-2 infection as assessed by the Investigator:~  1. Post-exposure population: exposure to an individual with a diagnosis of SARS-CoV-2 infection (index case). Note: Participants with recent exposure to a laboratory-confirmed index case must be asymptomatic and randomized within 5 days (120 hours) of collection of the index case's positive SARS-CoV-2 diagnostic test.~ 2. Pre-exposure population: Occupational, housing, recreational and/or social conditions that are likely to increase risk of exposure to SARS-CoV-2.~* Agrees to defer receipt of COVID-19 vaccination for minimum of 180 days (6 months) after dosing~Exclusion Criteria:~* Has received (1) a SARS-CoV-2 vaccine, (2) mAb or (3) convalescent plasma from a person who has recovered from COVID-19 or prior participation in SARS-CoV2 vaccine, convalescent plasma, or mAb clinical trial any time prior to participation in the study.~* Receipt of any investigational product within 30 days or 5 half lives before the day of enrollment.~* Is acutely ill or febrile 72 hours before or at Screening or has other COVID-19 symptoms including cough, fatigue, muscle or body aches, headache, or loss of taste or smell. Fever is defined as a body temperature ≥38.0°C (≥100.4°F).~* Has received or plans to receive a non-COVID-19 vaccine within 28 days before or after dosing (except for seasonal influenza vaccine, which is not permitted within 14 days before or after dosing).~NOTE: Other protocol defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ADG20 (Type: EXPERIMENTAL): Participants will be dosed on Day 1 with ADG20 IM
- Placebo (Type: PLACEBO_COMPARATOR): Participants will be dosed on Day 1 with placebo IM

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Development of a Predictive Score for Local Complications of Femoral Bifurcation Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient who has not opposed participation in the study~* Age \> 18 years old~* All patients with an open surgical approach to the common femoral artery and/or femoral bifurcation, uni or bilateral, with or without endovascular or open procedure~Exclusion Criteria:~* Patient with homolateral surgery of the femoral triangle which has not yet healed~* Person subject to court-ordered protection (curatorship, guardianship)~* Pregnant, parturient or breastfeeding woman~* Adult unable to consent~* Patient who refuses to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cortical Plasticity Assessment in Athletes With a History of Concussion

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Student-athletes at risk for traumatic brain injury (collegiate football, ice hockey)~* Age between 18 and 30 yr.~* Concussion as defined by the American Academy of Neurology: trauma-induced alteration in mental status that may or may not involve loss of consciousness (confusion and amnesia are the hallmarks of concussion)~* Concussion that occurred \> 6 months~* All head injuries classified as minor with a Glasgow Coma Scale of 13 to 15 at the time of the trauma~* Participants are cleared for full sport participation based upon neurological and neuropsychological (NS) assessments Classified as symptomatic based on Post-concussion Symptom List~Exclusion Criteria:~* Previous significant neurological history~* Use of tricyclic anti-depressants such as amitriptyline, nortriptyline and imipramine within the past six months.~* Use of anticonvulsants such as carbamazepine, phenytoin, valproic acid and gabapentin within the past six months~* History of seizures, depression or PTSD~* Presence of post-concussion symptoms such as complaints of loss of concentration, dizziness, fatigue, headache, irritability, visual disturbances, and light sensitivity.~* Contraindications to single pulse TMS (TMS will be used to measure cortical excitability) such as metal head implants~* history of seizures~* unexplained loss of consciousness~* metal in the head~* frequent or severe headaches or neck pain~* implanted brain medical devices.~* Contraindications to tDCS:~* metal in the head~* implanted brain medical devices~For the control group (subjects with no concussion) we will select subjects according to the previously stated list of exclusions as well as the following criteria: Subjects who are athletes (similar to the concussed group) with the same age range and also similar level of education; however these subjects will have no prior history of concussion or neurological insult as self reported. They should also have no contraindications to TMS or tDCS.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Subjects (Type: EXPERIMENTAL): Each subject will undergo each of the three conditions (active anodal tDCS, cathodal tDCS and sham tDCS), but the order in which they do so will be randomized.
- Athletes with history of concussion (Type: EXPERIMENTAL): Each subject will undergo each of the three conditions (active anodal tDCS, cathodal tDCS and sham tDCS), but the order in which they do so will be randomized.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Tele-expertise in Patients With Diabetes Hospitalized for Covid-19 Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient adult hospitalized for Covid-19 infection in the Infectious Diseases Department of the University Hospital of Strasbourg (HUS)~* Patient requiring steroid treatment~* Diabetic patient (type 1,2, MODY, secondary) or with corticosteroid-induced diabetes following initiation of corticosteroid treatment~Exclusion Criteria:~* Contraindication to the use of the Free-Style Medical Device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tele-expertise (Type: NO_INTERVENTION): Basal-bolus insulin treatment with adaptation of insulin doses according to continuous glucose measurement
- Standard (Type: EXPERIMENTAL): Standard treatment and adaptation of insulin doses according to the usual management of the unit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Post-Approval Clinical Study of the Talent Thoracic Stent Graft to Treat Thoracic Aortic Aneurysms (THRIVE)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: appropriate anatomy for elective repair of the descending thoracic aortic aneurysm~* iliac/femoral access vessel morphology that is compatible with vascular access techniques, devices, and or accessories~* non-aneurysmal aortic diameter in the range of 18-42mm; and~* non-aneurysmal aortic proximal and distal neck lengths equal to or greater than 20mm~* subject has a Descending Fusiform Thoracic Aneurysm = to or greater than 5cm in diameter OR is = to or greater than 2 times the diameter of the non-aneurysmal thoracic aorta and/or saccular aneurysms/penetrating ulcers~* Signed patient informed consent~Exclusion Criteria:~* Less than 18 yrs old~* pregnant~* unable to comply w/follow-up~* participating in other drug or device trials;~* Subject has a co-morbidity causing expected survival to be less than 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DeNovo (Type: EXPERIMENTAL): Prospectively enrolled subjects treated with the Talent Thoracic Stent Graft System following U.S. market approval of the device.
- Valor (Type: NO_INTERVENTION): Historical control arm, consisting of 195 subjects from the VALOR Test Group (PMA P070007) that were followed for 5 years per the VALOR protocol. The data from these subjects will be combined with the data from the subjects implanted after commercial release (DeNovo) to comprise the final analysis cohort for the THRIVE Study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Positive Airway Pressure and Cardiometabolic Risk

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Body mass index greater than 95th percentile for age and gender~2. Moderate to severe obstructive sleep apnea (OSA) (as defined by an apnea-hypopnea index (AHI) score of ≥5 events per hour).~Only patients who provide informed assent or consent and also have consent from a parent will be included.~Exclusion Criteria:~1. Predominant central sleep apnea~2. Type 1 Diabetes~3. Type 2 Diabetes~4. Requires use of supplemental oxygen~5. Active infection, cancer, or chronic inflammatory disorder~6. Use of systemic steroids~7. Simultaneous use of peroxisome proliferator-activated receptor (PPAR)-alpha (e.g., gemfibrozil, fenofibrate) or PPAR-gamma (e.g., rosiglitazone, pioglitazone)

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- CPAP/Bi-PAP (Type: EXPERIMENTAL): Subjects will be treated with either CPAP or Bi-PAP for three months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 and more~* Diffuse long native coronary artery stenosis (\>50% by visual estimate) with lesion length of more than 40 mm requiring at least 2 overlapped stents with a reference-vessel diameter of 2.5 to 3.75 mm on visual assessment~* Patients with silent ischemia, stable or unstable angina pectoris, and acute myocardial infarction including NSTEMI or STEMI~* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site~Exclusion Criteria:~* Subject has known hypersensitivity or contraindication to device material and its ingredients (everolimus, poly(L-lactide), poly(DL-lactide), lactide, lactic acid) and cobalt, chromium, nickel, platinum, tungsten, acrylic, and fluoro polymers that cannot be adequately premedicated~* Subject has known allergic reaction, hypersensitivity, or contraindication to aspirin; to clopidogrel and prasugrel and ticagrelor; or to heparin and therefore cannot be adequately treated with study medication~* An elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs within 12 m after the procedure~* STEMI requiring primary percutaneous coronary intervention~* Cardiogenic shock~* Restenotic lesions~* Left main~* Extreme angulation (≥90°) or excessive tortuosity (≥two 45° angles) proximal to or within the target lesion~* Heavy calcification proximal to or within the target lesion~* Compromised left ventricular dysfunction (LVEF \<30%)~* At the time of screening, the subject has a malignancy that is not in remission~* Terminal illness with life expectancy \<1 year~* Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period~* Patient's pregnant or breast-feeding or child-bearing potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABSORB BVS (Type: EXPERIMENTAL): None
- XIENCE EES (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Pain, Agitation and Delirium (PAD) Protocol in the Duke CICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients admitted to the Duke CICU, who require intubation and sedation for mechanical ventilation that is expected to be \>24 hours in duration will be included, unless they meet the specified exclusion criteria.~* Patients intubated within one hour prior to care transition to the CICU will also be screened for inclusion.~Exclusion Criteria:~* Exclusion criteria include patients following resuscitation from cardiac arrest who are treated on the cooling protocol~* patients who have suffered a neurologic event (seizure, stroke) or who have baseline dementia, both of which could limit delirium assessment~* patients with child class B and C liver disease~* patients with known allergy to study medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Midazolam (Type: ACTIVE_COMPARATOR): IV midazolam will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
- Propofol or Dexmedetomidine (Type: ACTIVE_COMPARATOR): Propofol or Dexmedetomidine per physician discretion will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed carcinoma of the breast~* Locally advanced and/or metastatic disease~* Deleterious or pathogenic germline BRCA 1 or BRCA 2 mutation~* Prior chemotherapy: Cohort 1) PR or CR to prior platinum-containing regimen for metastatic disease with disease progression \> 8 weeks following the last dose of platinum; or Cohort 2) \> 2 prior chemotherapy regimens for metastatic disease and no prior platinum for metastatic disease~* ECOG performance status ≤ 1~* Have adequate organ function~Exclusion Criteria:~* Prior enrollment into a clinical trial of a PARP inhibitor~* CNS metastasis except adequately treated brain metastasis documented by baseline CT or MRI scan that has not progressed since previous scans and that does not require corticosteroids for management of CNS symptoms~* Prior malignancy except for prior BRCA-associated cancer as long as there is no current evidence of the prior cancer, carcinoma in situ of the cervix or non-melanoma skin cancer, and a cancer diagnosed and definitively treated \>5 years prior to study enrollment with no subsequent evidence of recurrence~* Known to be HIV positive, active hepatitis C virus, or active hepatitis B virus~* Known hypersensitivity to any of the components of talazoparib

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- talazoparib (Type: EXPERIMENTAL): Cohort 1) Subjects with a documented PR or CR to a prior platinum-containing regimen for metastatic disease with disease progression \> 8 weeks following the last dose of platinum~Cohort 2) Subjects who have received \> 2 prior chemotherapy regimens for metastatic disease and who have had no prior platinum therapy for metastatic disease

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of the Peregrine Drivable ENT Scope for Endoscopy of the Paranasal Sinuses

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A male or female patient who has had prior ESS and who is indicated for office endoscopy by the ENT specialist~* A patient who is able to understand the requirements of the study, is willing to comply with its instructions and schedules, and agrees to sign the informed consent form~Exclusion Criteria:~* Any medical disorder which in the investigator's judgment contraindicates the patient's participation~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard 30° 4mm Endoscope Followed by Peregrine Endoscope (Type: EXPERIMENTAL): Participants will receive an endoscopy with the standard 30° 4mm endoscope followed by an endoscopy with the Peregrine Drivable ENT Scope.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility